Advertisement

Topics

Cancer Diagnostics 2021: Supplier Shares and Market Segmnet Forecasts by TestsA Market on the Verge of ExplosionTechnological Breakthroughs, Emerging Tests, Competitive Intelligence [Report Updated: 23102017] Prices from USD $24500

07:37 EST 11 Nov 2017 | BioPortfolio Reports

Complete report $24,500.nbsp; DataPack test volumes, sales forecasts, supplier shares $15,900.

VPGMarketResearchrsquo;s new report is a study of the major business opportunities emerging in the global cancer diagnostics market during the nextnbsp;five years. The report examines trends in the U.S., Europe and Japan; reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

Geographic Coverage

France, Germany, Italy, Japan, Spain, UK, USA

Worldwide Market Overview

Fiveyear test volume and sales projections by country.

Comprehensive market segmentation analysis, including review

of the market dynamics, structure, size, growth and major suppliers by country.

Estimated universe of laboratories performing cancer diagnostic testing by country.

Cancer statistics, etiology and recent developments in the U.S., Europe, and Japan.

Business Opportunities and Strategic Recommendations

Specific new product development opportunities with potentially

significant market appeal during the next five years.

Design criteria for new products.

Alternative market penetration strategies.

Potential market entry barriers and risks.

Over 200 Current and Emerging Cancer Diagnostic Test

Biochemical Markers

Oncogenes

Growth Factors

Hormones

Colony Stimulating Factors

Lymphokines

Immunohistochemical Stains, and others.

ACTH, AFP, Beta2 Microglobulin, CA 153/27.29, CA 199, CA 125, Calcitonin, Cathepsin, CEA,

Chromogranin, ColonSpecific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG,

Insulin, Interferons, Interleukins, Lymphocyte Subtyping, NeuronSpecific Enolase, Nucleolar,

Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone,

Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S100 Protein,

Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin,

Tissue Polypeptide Antigen, and others.

Supplier Shares, Sales and Volume Forecasts

Sales and market shares of major cancer diagnostic product

suppliers by individual test and country.

Fiveyear test volume and sales forecasts

for major tumor markers by country and market segment, including:

Hospitals

Commercial/Private Laboratories

Physician Offices/Group Practices

Cancer Clinics

Ambulatory Care Centers

Instrumentation Review

Analysis of major molecular diagnostic and immunodiagnostic analyzers

used for cancer testing, including their operating characteristics,

features and selling prices.

Technology Assessment

Assessment of latest molecular diagnostic methods,

biochips/microarrays, biosensors, monoclonal antibodies, immunoassays,

chromosome analysis, IT, artificial intelligence, flow cytometry, and other technologies

and their potential applications for cancer diagnostic testing.

Review of competing/complementing technologies, including

CT, MRI, NMR, PET and photonics spectroscopy.

Extensive listings of companies, universities

and research centers developing new cancer diagnostic tests

and detection technologies.

Competitive Strategies

Strategic assessments ofnbsp;major suppliers

and startup firms developing innovative

technologies and products, including their sales,

product portfolios, marketing tactics, collaborative

arrangements, and new products in Ramp;D.

The companies analyzed in the report include:

nbsp;nbsp; Abbott

nbsp;nbsp; AdnaGen

nbsp;nbsp; Agilent Technologies

nbsp;nbsp; Applied Gene Technologies

nbsp;nbsp; Arca Biopharma

nbsp;nbsp; Beckman Coulter/Danaher

nbsp;nbsp; Becton Dickinson

nbsp;nbsp; Biomedical Diagnostics

nbsp;nbsp; bioMerieux

nbsp;nbsp; BioRad

nbsp;nbsp; CellSearch

nbsp;nbsp; Cepheid

nbsp;nbsp; Correlogic Systems/Vermillion

nbsp;nbsp; Decode Genetics

nbsp;nbsp; Diadexus

nbsp;nbsp; Diagnocure

nbsp;nbsp; DiaSorin

nbsp;nbsp; Eiken Chemical

nbsp;nbsp; Elitech Group

nbsp;nbsp; Enterix

nbsp;nbsp; Enzo Biochem

nbsp;nbsp; Epigenomics

nbsp;nbsp; Fujirebio

nbsp;nbsp; Guided Therapeutics

nbsp;nbsp; Hologic/GenProbe

nbsp;nbsp; Kreatech/Leica

nbsp;nbsp; Kyowa Medex

nbsp;nbsp; Mackay Life Sciences

nbsp;nbsp; Myriad Genetics

nbsp;nbsp; OncoLab

nbsp;nbsp; OrthoClinical Diagnostics

nbsp;nbsp; Panacea Pharmaceuticals

nbsp;nbsp; Polartechnics

nbsp;nbsp; Polymedco

nbsp;nbsp; PreMD

nbsp;nbsp; Qiagen

nbsp;nbsp; Quest Diagnostics

nbsp;nbsp; Radient Pharmaceuticals

nbsp;nbsp; Roche

nbsp;nbsp; Scienion

nbsp;nbsp; Sequenom

nbsp;nbsp; Siemens Healthcare

nbsp;nbsp; Takara Bio

nbsp;nbsp; Targeted Diagnostics amp; Therapeutics

nbsp;nbsp; Thermo Fisher

nbsp;nbsp; Tosoh

nbsp;nbsp; Veridex

nbsp;nbsp; Wako Pure Chemicals

nbsp;nbsp; Wallac/PE

nbsp;nbsp; Zilla

Contains 1,200 pages and 450 tables

Original Article: Cancer Diagnostics 2021: Supplier Shares and Market Segmnet Forecasts by TestsA Market on the Verge of ExplosionTechnological Breakthroughs, Emerging Tests, Competitive Intelligence [Report Updated: 23102017] Prices from USD $24500

NEXT ARTICLE

More From BioPortfolio on "Cancer Diagnostics 2021: Supplier Shares and Market Segmnet Forecasts by TestsA Market on the Verge of ExplosionTechnological Breakthroughs, Emerging Tests, Competitive Intelligence [Report Updated: 23102017] Prices from USD $24500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Immunoassay - ELISA
Immunoassays are quick and accurate tests to detect specific molecules. Immunoassays rely on an antibody to bind to the specific structure of a molecule. Antibodies are proteins generated by animals in response to the invasion of a foreign molecule (anti...